RxDoctor Payments Data

Jennifer Wong

Physician Assistant · Fresh Meadows, NYNPI 1871837906

Payments from drug & device makers

$17,860in general payments, 2019–2025

Across 638 payments — averaging $27.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Dermavant Sciences, Inc.$2K
  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Sanofi$1K
  • Pfizer$1K
  • plus $9K from 24 others

What the payments were for

  • Consulting fees$3,21118%
  • Travel & lodging$500%
  • Food & beverage$13,94478%
  • Education$6554%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,860 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$209,028
Medicare patients
318
Services billed
3,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab26$95,399
SotyktuDeucravacitinib12$74,724
OpzeluraRuxolitinib Phosphate18$39,915
ZoryveRoflumilast26$21,502
JubliaEfinaconazole11$16,958
EucrisaCrisaborole16$12,358
Tacrolimus64$11,621
Calcipotriene41$9,556
Ketoconazole408$7,986
Fluocinonide149$5,923
Clobetasol Propionate138$5,504
Betamethasone Valerate188$4,346
Clindamycin Phosphate88$3,251
Tretinoin58$3,033
Metronidazole62$2,537

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Sotyktu$1,203$74,72412 claims
Incyte CorporationOpzelura$969$39,91518 claims
Arcutis Biotherapeutics, Inc.Zoryve$744$21,50226 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$65$16,95811 claims
PfizerEucrisa$1,051$12,35816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Fresh Meadows

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →